PHOENIX and BRITISH COLUMBIA, Canada, Sept. 19 /PRNewswire-FirstCall/ --
St. Joseph's Hospital and Medical Center, part of Catholic Healthcare West,
one of the largest healthcare systems in the West with 42 hospitals in
Arizona, California and Nevada and InNexus Biotechnology Inc.,
(OTC Bulletin Board: IXSBF; TSX VENTURE: IXS; http://www.ixsbio.com), a drug
development company commercializing the next generation of monoclonal
antibodies based on its Dynamic Cross Linking (DXL(TM)) technology, announces
a collaborative partnership focusing on the development of treatments for
women with endometriosis.
"I am pleased to announce this new partnership between St. Joseph's
Hospital and InNexus to explore, develop and commercialize new therapeutic
solutions for women," said Jeff Morhet, Chairman and CEO of InNexus
Biotechnology, "We've already identified our first project, aimed at providing
new treatments to attack the problem of endometriosis, a painful condition
that can lead to other conditions, such as infertility."
"We're excited to join InNexus in pursuing new treatments to help women
with endometriosis," says Linda Hunt, President of St. Joseph's. "We hope this
is the first of many collaborations that will ultimately help patients in
need."
Scientific activities of the partnership will be conducted in facilities
of both St. Joseph's Hospital and Medical Center and InNexus' GLP (Good Lab
Practice) certified drug development laboratories with funding provided by
research grants, the partners and strategic collaborators. Additional details
were not disclosed.
About Endometriosis
According to the National Institutes of Health, endometriosis occurs when
tissues that usually grow inside the uterus instead grow on the outside.
These tissues often grow on the surfaces of organs in the pelvis or abdomen,
where they are not supposed to grow.
Endometriosis is one of the most common gynecological diseases, affecting
more than 5.5 million women in North America. An estimated 2 to 10 percent of
women of reproductive age have endometriosis. Additional information can be
found at http://www.nichd.nih.gov/health/topics/endometriosis.cfm.
About St. Joseph's Hospital and Medical Center
Located in the heart of Phoenix, Arizona, St. Joseph's Hospital and
Medical Center is a 743-bed, not-for-profit hospital that is recognized for
outstanding patient care, medical education and research. The hospital is
part of Catholic Healthcare West (CHW), one of the largest healthcare systems
in the West with 42 hospitals in Arizona, California and Nevada. You can find
out more about St. Joseph's Hospital and Medical Center at
http://www.stjosephs-phx.org.
About InNexus
InNexus is a drug development company commercializing the next generation
of monoclonal antibodies based on its DXL(TM) technology, which improves the
potency of existing antibody products while opening new markets and disease
applications. DXL(TM) antibodies utilize unique, novel and patented methods
and technologies of InNexus.
InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit http://www.ixsbio.com.
The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control that may cause actual
results or performance to differ materially from those currently anticipated
in such statements.
SOURCE InNexus Biotechnology Inc.; St. Joseph's Hospital and Medical Center